Back to search results

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer · HER2-positive Breast Cancer · ER Positive Breast Cancer · PR-Positive Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Illinois Cancer Center, Chicago, Illinois, United States

    Contact: Principal Investigator (Oana Danciu, MD)

  • University of Rochester Medical Center, Rochester, New York, United States

    Contact: Study coordinator (Lisa Carrozzi, OCN) · lisa_carrozzi@urmc.rochester.edu · 585-533-1905
    Contact: Study coordinator (Kathleen Pratt) · kathleen_pratt@urmc.rochester.edu · 585-533-1908
    Contact: Principal Investigator (Ruth O'Regan, MD)

  • Penn State Cancer Institute, Hershey, Pennsylvania, United States

    Contact: Study coordinator (Cindy Brown) · cbrown18@pennstatehealth.psu.edu
    Contact: Principal Investigator (Monali Vasekar, MD)

  • University of Wisconsin, Madison, Wisconsin, United States

    Contact: Study coordinator (UW Cancer Connect) · 800-622-8922
    Contact: Principal Investigator (Kari Wisinski, MD)
Study leads

  • Ruth O'Regan, MD

    Principal Investigator

    University of Rochester

View source on ClinicalTrials.gov(opens in a new tab)